Shenzhen YHLO Biotech (SH:688575) 梧桐树下V·2026-02-06 12:57Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yahui Long Biotechnology Co., Ltd. for allegedly misleading statements in their announcement regarding a strategic cooperation framework agreement [1] Group 1: Company Overview and Business Model - Yahui Long was listed on May 17, 2021, and primarily engages in the research, production, and sales of in vitro diagnostic instruments and related reagents, focusing on chemiluminescence immunoassay methods [2] - The company signed a strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. on January 6, 2026, which was announced on January 7, 2026 [2] Group 2: Strategic Cooperation Details - The cooperation aims to leverage Yahui Long's strong sales channels and expert resources in emergency, brain disease diagnosis, and pediatrics, combined with Brain Machine Star Chain's technical team and R&D capabilities in brain-machine interface technology [4] - The agreement includes comprehensive support for market expansion and sales of Brain Machine Star Chain's existing and in-development products, with revenue sharing to be determined in future agreements [5] - The collaboration will enhance R&D efforts in areas such as stroke, neurodegenerative diseases, and pediatric disorders, aiming for a comprehensive layout in brain disease diagnosis and treatment [7] Group 3: Impact on Company Performance - The strategic cooperation agreement is currently non-binding and is not expected to significantly impact Yahui Long's financial performance in the current year; future impacts will depend on the progress of specific projects [8] - The partnership is expected to enhance Yahui Long's competitiveness in central nervous system diseases and expand its strategic layout in brain-machine interface technology, aligning with the company's long-term development strategy [8] Group 4: Market Reactions and Stock Performance - Following the signing of the cooperation agreement on January 6, the company's stock price rose by 6.52%, and it opened significantly higher at 17 yuan on January 7, reflecting a 9.47% increase [10] - The Shanghai Stock Exchange has requested Yahui Long to disclose insider trading information related to the announcement of the framework agreement, as trading volume increased by 299% on January 6 [12] Group 5: Financial Forecasts - Yahui Long has projected a significant decline in net profit for the year 2025, estimating a range of 20 million to 30 million yuan, which represents a decrease of 90.05% to 93.37% compared to the previous year [13][15] - The company also anticipates a decrease in net profit after deducting non-recurring gains and losses, estimating between 65 million to 85 million yuan, a reduction of 70.42% to 77.38% year-on-year [15]